|
|
Article: Investor Alert for Advancis Pharmaceutical Corp.
- Article from:
- M2 Presswire
- Article date:
- February 14, 2007
CopyrightCOPYRIGHT 2007 M2 Communications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-14 February 2007-Biotech News: Investor Alert for Advancis Pharmaceutical Corp.(C)1994-2007 M2 COMMUNICATIONS LTD
RDATE:14022007
Advancis Pharmaceutical Corporation has its fingers on the pulse in the fight against bacteria. The company is developing new formulations of existing antibiotics that are no longer patent protected, using its PULSYS once-a-day pulsatile delivery technology. Among the antibiotics that the company is researching are amoxicillin, cephalexin, and clarithromycin. Advancis is looking to collaborate with other drugmakers to use its PULSYS technology; the company already has made a deal with Eli Lilly to develop a PULSYS ...